Indian stocks: Visit www.stage2stocks.com →

RenovoRx, Inc.

Stage 2 · Advancing · week 10

As of Oct 22, 2026, RenovoRx is in Stage 2, the uptrend phase, now in week 10 (since Aug 13, 2026). It closed at $1.27, 49.6% below its 52-week high and above its 200-day average, which is rising.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. More about the company

$1.27
+4.96% today
$57.3M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is RNXT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 20w
S4 17w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 20w → S1 12w → S2 1w → S3 1w → S2 1w → S3 6w → S4 2w → S3 5w → S4 17w → S1 6w → S2 8w → S3 4w → S4 8w → S1 4w → S2 8w → S3 3w → S4 7w → S2 3w → S3 1w → S4 11w → S1 5w → S4 4w → S1 2w → S4 13w → S1 2w → S2 10w current
Total tracked: 165 weeks across 26 stage runs.

RNXT among Biotechnology162nd of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…162RNXTStage 2 · wk 1060−22.1%
vs 52W High
-49.6%
$0.73 lo$2.52 hi
49.6% below 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 10
1w13w26w
Week 10, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
16.1%
200 DMA: $1.09 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.24x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-22.1%
3M
+46.8%
6M
+41.1%
YTD
+52.1%
1Y
+6.7%
Scan Membership
Breakout Watch
Latest: 2025-06-18
5 appearances in last 60 days. First seen: 2023-01-12.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 10 · Vol 0.24x
2026-10-21S2
Wk 10 · Vol 0.42x
2026-10-20S2
Wk 10 · Vol 0.28x
2026-10-19S2
Wk 10 · Vol 0.31x
2026-10-16S2
Wk 10 · Vol 0.29x
2026-10-15S2
Wk 9 · Vol 0.35x
2026-10-14S2
Wk 9 · Vol 0.66x
2026-10-13S2
Wk 9 · Vol 1.00x
2026-10-12S2
Wk 9 · Vol 0.27x
2026-10-09S2
Wk 9 · Vol 0.86x
2026-10-08S2
Wk 8 · Vol 0.48x
2026-10-07S2
Wk 8 · Vol 0.65x
Moving averages & range
50 DMA
$1.55
200 DMA
$1.09
52W High
$2.52
52W Low
$0.73
5D Low
$1.14
Resistance levels (recent highs)
20d High
$1.66
60d High
$2.52
120d High
$2.52
250d High
$2.52
Next resistance
+30.7%
to 20d High
ROE
-125.2%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 6.4

RenovoRx: quick answers

What stage is RenovoRx in?

As of Oct 22, 2026, RenovoRx (RNXT) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 13, 2026 and is in week 10. What the four stages mean

Is RenovoRx in an uptrend?

Yes. RenovoRx is in a Stage 2 uptrend. It trades 16.1% above its 200-day average, which is rising.

How far is RenovoRx from its 52-week high?

RenovoRx closed at $1.27 on Oct 22, 2026, 49.6% below its 52-week high of $2.52. Its 52-week low is $0.73.

How has RenovoRx performed over the past year?

As of Oct 22, 2026, RenovoRx is up 6.7% over the past year and up 52.1% so far in 2026.

Which sector and industry is RenovoRx in?

RenovoRx is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.